mAb 222
An anti-SARS-CoV-2 monoclonal antibody.
General information
mAb 222 is a monoclonal antibody neutralizing SARS-CoV-2 (Supasa et al., 2021). It has been identified in a B cell of a COVID-19 convalescent patient (Dejnirattisai et al., 2021). mAb 222 binds the Beta variant Spike protein (Liu et al., 2022) and neutralizes the Omicron variant in vitro (Dejnirattisai et al., 2022). It was also shown to neutralize the Delta and other variants of SARS-CoV-2 (Dejnirattisai et al., 2022; Liu et al., 2021; Supasa et al., 2021; Zhou et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Spike protein ACE2 RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
sera from vaccinated or convalescent individuals; VeroE6/TMPRSS2 cells; SARS-CoV-2 (various strains) | 41.58 | Neutralizes Omicron variant in vitro. |
Jan/04/2022 |
|
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
Spike protein Spike variant Cryo-EM Crystallization Novel compound Biophysical assay Protein factor Animal model In vitro Mechanism Antibody Screening |
in vitro biophysical assay; crystallization; cryo-EM; plasma of COVID-19 (Beta strain) convalescent patients; Vero cells; VeroE6/TMPRSS2 cells; Vero-hACE2-TMPRSS2 cells; K18-hACE C57BL/6J mice; SARS-CoV-2 (various strains) | 21.02 | mAb 222 binds the Beta variant Spike protein in vitro. |
Nov/27/2021 |
|
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Spike protein Spike variant Crystallization Protein factor In vitro Mechanism Antibody |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients or vaccinated adults; Vero cells; SARS-CoV-2 (SARS-CoV-2/human/AUS/VIC01/2020 and SAR-CoV-2/B.1.1.7) | 41.58 | Binds RBD and neutralizes SARS-CoV-2 in vitro without reduction in affinity in the case of the N501Y mutation. |
Feb/18/2021 |
|
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Spike protein Cryo-EM Crystallization Novel compound Protein factor In vitro Mechanism Antibody |
in vitro biophysical assay; crystallization; cryo-EM; sera of COVID-19 convalescent patients; Vero cells; K18-hACE C57BL/6J mice; SARS-CoV-2 (2019n-CoV/USA_WA1/2020 and SARS-CoV-2/human/AUS/VIC01/2020) | 41.58 | Neutralized SARS-CoV-2 in vitro. Its binding to RBD has been mapped. |
Feb/18/2021 |
|
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Spike protein RNA DNA Spike variant Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; plasma of COVID-19 (Beta strain) convalescent patients or vaccinated adults; Vero cells; SARS-CoV-2 (SARS-CoV-2/human/AUS/VIC01/2020 and SARS-CoV-2/B.1.351) | 41.58 | Binding of SARS-CoV-2 RBD and neutralization of the virus is unaffected in the case of the Beta variant. |
Feb/23/2021 |
|
Antibody evasion by the P.1 strain of SARS-CoV-2
Spike protein RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients and vaccinated adults; Vero cells; SARS-CoV-2 (Victoria, Alpha, Beta, and Gamma) | 41.58 | Neutralized all of the SARS-CoV-2 strains tested in vitro. |
Mar/30/2021 |
|
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Spike protein RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients and vaccinated adults; Vero cells; HEK293T/17-hACE2 cells; SARS-CoV-2 (Victoria, Alpha, Beta, and Delta); (HIV-1) SARS-CoV-2 Spike-pseudotyped virus (various variants) | 41.58 | The antibody neutralized the Delta variant of SARS-CoV-2 in vitro. |
Jun/17/2021 |
